Trial record 19 of 23 for:
" November 21, 2007":" December 21, 2007"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults (ITAP)
This study has been completed.
Sponsor:
University of Aarhus
Collaborator:
Aarhus University Hospital
Information provided by:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT00562939
First received: November 23, 2007
Last updated: January 20, 2009
Last verified: January 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether TLR-9 adjuvanted pneumococcal is more immunogenic than pneumococcal vaccination alone in HIV-infected adults.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections |
Biological: Pneumococcal vaccines + CPG 7909 Biological: Pneumococcal vaccines |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults |
Resource links provided by NLM:
Further study details as provided by University of Aarhus:
Primary Outcome Measures:
- Numbers of vaccine high responders - defined as 2-fold increase and IgG levels ≥1 µg/mL to at least 5 of 7 pneumococcal serotypes (by quantitative IgG measurements) - in the CpG 7909 group vs. the control group [ Time Frame: At day 270 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Functional activity of anticapsular antibodies measured by OPA [ Time Frame: At day 90, 120, 270, 300 ] [ Designated as safety issue: No ]
- Safety/Tolerability [ Time Frame: During the entire trial period ] [ Designated as safety issue: Yes ]
- Nasopharyngeal pneumococcal colonization [ Time Frame: At day 270 ] [ Designated as safety issue: No ]
- Predictors of antibody response, i.e. CD4+ cell count and sCD163 [ Time Frame: At baseline ] [ Designated as safety issue: No ]
- Numbers of vaccine high responders - defined as 2-fold increase and IgG levels ≥1 µg/mL to at least 5 of 7 pneumococcal serotypes (by quantitative IgG measurements) - in the CpG 7909 group vs. the control group [ Time Frame: At day 90,120 and 300 ] [ Designated as safety issue: No ]
- Quantity and differentiation of IgG subtypes for HAART-experienced and HAART-naive individuals [ Time Frame: Day 0, 90, 120 ] [ Designated as safety issue: No ]
- Cytokine response to various antigens by in vitro cell stimulation for HAART-experienced and HAART-naive individuals [ Time Frame: At day 0, 90, 120 ] [ Designated as safety issue: No ]
| Enrollment: | 97 |
| Study Start Date: | January 2008 |
| Study Completion Date: | January 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
1 mg CpG 7909 + pneumococcal vaccines
|
Biological: Pneumococcal vaccines + CPG 7909
Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
Other Name: Cpg 7909/Vaximmune(TM)
|
|
Placebo Comparator: B
Pneumococcal vaccines
|
Biological: Pneumococcal vaccines
Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
|
Detailed Description:
Pneumococcal disease is a major source of morbidity and mortality in HIV-patients. HIV-patients are vaccine hyporesponders. A good immune response to pneumococcal vaccination enhances vaccine effectiveness, thereby preventing the morbidity and mortality caused by pneumococcal disease. Even when an optimized regimen containing both conjugated and polysaccharide pneumococcal vaccine is used, only 13% of the immunized HIV patients are high responders at week 96. Recent data indicate that TLR9-agonists have excellent vaccine adjuvant potential and are safe to use in immunocompetent as well as immunocompromised individuals. The aim of this study is to evaluate the qualitative and quantitive immune response to pneumococcal vaccination with or without TLR9-agonist in HIV-infected adults
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written informed consent and authority statement provided according to local regulatory and ethical practice using a participant information sheet and informed consent form approved by the responsible Ethics Committee.
- HIV-seropositive individuals.
Exclusion Criteria:
- Pregnancy as determined by a positive urine beta-hCG (if female)
- Participant unwilling to use reliable contraception methods for the duration of the trial. Reliable methods of birth control include: pharmacologic contraceptives including oral, parenteral, and transcutaneous delivery; condoms with spermicide; diaphragm with spermicide; surgical sterilization; vaginal ring; intrauterine device; abstinence; and post-menopause (if female)
- Currently breast-feeding (if female)
- Latest CD4 count < 200 x106 cells/µL
- Viral load (HIV RNA) > 50 copies/mL if on HAART (defined as at least three antiretrovirals including either a protease inhibitor or a NNRTI, i.e. combivir 300/150 mg x2 + stocrin 600 mg x1 for a minimum of 6 months)
- Previous enrollment in this study
- Any medical, psychiatric, social, or occupational condition or other responsibility that, in the judgment of the Principal Investigator (PI), would interfere with the evaluation of study objectives (such as severe alcohol abuse, severe drug abuse, dementia)
- Unable to follow protocol regimen
- Pneumococcal vaccination 5 years or less prior to inclusion
- Planned participation in other vaccination trials during the time of the study
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00562939
Please refer to this study by its ClinicalTrials.gov identifier: NCT00562939
Locations
| Denmark | |
| Department of Infectious Diseases, Aarhus University Hospital | |
| Aarhus, Denmark, 8200 | |
Sponsors and Collaborators
University of Aarhus
Aarhus University Hospital
Investigators
| Principal Investigator: | Ole Sogaard, MD | Department of Infectious Diseases, Aarhus University Hospital, Denmark |
| Study Director: | Lars Ostergaard, MD,PhD,DmSC | Department of Infectious Diseases, Aarhus University Hospital, Denmark |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Ole Søgaard, MD, Department of Infectious Diseases, Skejby |
| ClinicalTrials.gov Identifier: | NCT00562939 History of Changes |
| Other Study ID Numbers: | 2007-001588-31 |
| Study First Received: | November 23, 2007 |
| Last Updated: | January 20, 2009 |
| Health Authority: | Denmark: Danish Dataprotection Agency Denmark: Danish Medicines Agency Denmark: The Danish National Committee on Biomedical Research Ethics Denmark: The Regional Committee on Biomedical Research Ethics |
Keywords provided by University of Aarhus:
|
Antibody Formation Antibody Affinity Immunity Pneumococcal Vaccines Oligodeoxyribonucleotides |
Additional relevant MeSH terms:
|
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Immunologic Deficiency Syndromes Immune System Diseases Vaccines Heptavalent Pneumococcal Conjugate Vaccine Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on September 26, 2016